Clinical Trial Update: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating once-weekly Petrelintide versus placebo for obesity or overweight with co-morbidities has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Petrelintide (Petrelintide)

Snippet

Sponsor: Zealand Pharma | Conditions: Obesity | Phase 2 | Status: COMPLETED